» Articles » PMID: 12204530

The RB and P53 Pathways in Cancer

Overview
Journal Cancer Cell
Publisher Cell Press
Specialty Oncology
Date 2002 Sep 3
PMID 12204530
Citations 627
Authors
Affiliations
Soon will be listed here.
Abstract

The life history of cancer cells encompasses a series of genetic missteps in which normal cells are progressively transformed into tumor cells that invade surrounding tissues and become malignant. Most prominent among the regulators disrupted in cancer cells are two tumor suppressors, the retinoblastoma protein (RB) and the p53 transcription factor. Here, we discuss interconnecting signaling pathways controlled by RB and p53, attempting to explain their potentially universal involvement in the etiology of cancer. Pinpointing the various ways by which the functions of RB and p53 are subverted in individual tumors should provide a rational basis for developing more refined tumor-specific therapies.

Citing Articles

Cyclin-Dependent Kinase Inhibition in Prostate Cancer: Past, Present, and Future.

Siskin M, Economides M, Wise D Cancers (Basel). 2025; 17(5).

PMID: 40075623 PMC: 11898528. DOI: 10.3390/cancers17050774.


Old drugs, new challenges: reassigning drugs for cancer therapies.

Czechowicz P, Wiech-Walow A, Slawski J, Collawn J, Bartoszewski R Cell Mol Biol Lett. 2025; 30(1):27.

PMID: 40038587 PMC: 11881393. DOI: 10.1186/s11658-025-00710-0.


Oncolytic Viruses in Ovarian Cancer: Where Do We Stand? A Narrative Review.

Borella F, Carosso M, Chiparo M, Ferraioli D, Bertero L, Gallio N Pathogens. 2025; 14(2).

PMID: 40005517 PMC: 11858389. DOI: 10.3390/pathogens14020140.


Discovery of paradoxical genes: reevaluating the prognostic impact of overexpressed genes in cancer.

Liu D, Liu L, Che X, Wu G Front Cell Dev Biol. 2025; 13:1525345.

PMID: 39911323 PMC: 11794808. DOI: 10.3389/fcell.2025.1525345.


Predictive Value of the Loss of pRb Expression in the Malignant Transformation Risk of Oral Potentially Malignant Disorders: A Systematic Review and Meta-Analysis.

Lopez-Ansio M, Ramos-Garcia P, Gonzalez-Moles M Cancers (Basel). 2025; 17(2).

PMID: 39858110 PMC: 11764026. DOI: 10.3390/cancers17020329.